SCHEMBL10102246

SCHEMBL10102246

Cc1ccc(C2(c3ccccc3)C=Cc3c(C(=O)OC4CCCCC4)cc4cc(C)ccc4c3O2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
TDP1 Q9NUW8 1/20 0.37
ADORA2B P29275 3/20 0.35
ALDH1A1 P00352 5/20 0.35
MAPK1 P28482 5/20 0.35
KDM4E B2RXH2 2/20 0.35
RAD52 P43351 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ALOX15 P16050 2/20 0.33
HSD17B10 Q99714 2/20 0.33
TP53 P04637 2/20 0.32
LMNA P02545 2/20 0.31
MAPT P10636 2/20 0.31
NPSR1 Q6W5P4 1/20 0.31
MAPK10 P53779 1/20 0.31
F12 P00748 1/20 0.31
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6650438 0.98 MEN1 (0.41) MEN1KMT2ANPC1RAB9ATDP1
SCHEMBL6651700 0.93 MEN1 (0.38) MEN1KMT2ANPC1RAB9ATDP1
SCHEMBL6653732 0.91 MEN1 (0.40) MEN1KMT2ANPC1RAB9ATDP1
SCHEMBL6653085 0.88 KMT2A (0.39) MEN1KMT2ANPC1RAB9ATDP1
SCHEMBL5097833 0.88 MEN1 (0.40) MEN1KMT2ANPC1RAB9ATDP1
SCHEMBL5107478 0.83 NR4A2 (0.37) MEN1KMT2ATDP1ALDH1A1MAPK1
SCHEMBL6659223 0.81 KDM4E (0.38) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL6384117 0.79 ALDH1A1 (0.40) MEN1KMT2ATDP1ADORA2BALDH1A1
SCHEMBL5097781 0.78 KDM4E (0.37) MEN1KMT2ATDP1ALDH1A1MAPK1
SCHEMBL15277650 0.77 SLC6A4 (0.36) NPC1RAB9AALDH1A1TP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8308995-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-11-13 US disclosed
EP-2275418-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2012-10-17 EP disclosed
US-20120138876-A1 CHROMENE COMPOUND KASAI SOKO (JP) 2012-06-07 US disclosed
US-8147726-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-04-03 US disclosed
US-20110062396-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2011-03-17 US disclosed
EP-2275418-A1 CHROMENE COMPOUND Tokuyama Corporation (JP) 2011-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120138876-A1 CHROMENE COMPOUND CHRM1, CBX8, CBX7 MEN1 270/4885KMT2A 1084/4885NPC1 1130/4885
US-20110062396-A1 CHROMENE COMPOUND CDYL, NR0B1, NR1H2 MEN1 1800/4885KMT2A 3251/4885NPC1 809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.